Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-09

Study Completion Date

2020-12-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a first-in-human, Phase I, single-dose escalation clinical trial conducted in Chinese healthy volunteers. The safety, tolerability, and PK of HSK21542 injection in healthy volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese Volunteers

NCT02746315

Healthy

COMPLETED PHASE1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Volunteers

NCT02746302

Healthy

COMPLETED PHASE1

Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers

NCT04652297

Healthy

UNKNOWN PHASE1

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dosed of HSK36273 in Healthy Volunteers

NCT05742126

Healthy

COMPLETED PHASE1

A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers

NCT05023525

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HSK21542 0.2 μg/kg（15 min)

Healthy volunteers 0.2 μg/kg HSK21542

Group Type EXPERIMENTAL

HSK21542

Intervention Type DRUG

Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

HSK21542 0.5 μg/kg

Healthy volunteers 0.5 μg/kg HSK21542 or Placebo

Group Type EXPERIMENTAL

HSK21542

Intervention Type DRUG

Intravenous injection 0.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

HSK21542 1 μg/kg （15min)

Healthy volunteers 1 μg/kg HSK21542 or Placebo

Group Type EXPERIMENTAL

HSK21542

Intervention Type DRUG

Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

HSK21542 1 μg/kg （2min)

Healthy volunteers 1 μg/kg HSK21542 or Placebo

Group Type EXPERIMENTAL

HSK21542

Intervention Type DRUG

Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.

HSK21542 0.75 μg/kg

Healthy volunteers 0.75 μg/kg HSK21542 or Placebo

Group Type EXPERIMENTAL

HSK21542

Intervention Type DRUG

Intravenous injection 0.75 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

HSK21542 1.5 μg/kg

Healthy volunteers 1.5 μg/kg HSK21542 or Placebo

Group Type EXPERIMENTAL

HSK21542

Intervention Type DRUG

Intravenous injection 1.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

HSK21542 2.25 μg/kg

Healthy volunteers 2.25 μg/kg HSK21542 or Placebo

Group Type EXPERIMENTAL

HSK21542

Intervention Type DRUG

Intravenous injection 2.25 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

HSK21542 3.375 μg/kg

Healthy volunteers 3.375 μg/kg HSK21542 or Placebo

Group Type EXPERIMENTAL

HSK21542

Intervention Type DRUG

Intravenous injection 3.375 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

HSK21542 0.2 μg/kg（2min)

Healthy volunteers 0.2 μg/kg HSK21542 or Placebo

Group Type EXPERIMENTAL

HSK21542

Intervention Type DRUG

Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HSK21542

Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

Intervention Type DRUG

HSK21542

Intravenous injection 0.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

Intervention Type DRUG

HSK21542

Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

Intervention Type DRUG

HSK21542

Intravenous injection 1 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.

Intervention Type DRUG

HSK21542

Intravenous injection 0.75 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

Intervention Type DRUG

HSK21542

Intravenous injection 1.5 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

Intervention Type DRUG

HSK21542

Intravenous injection 2.25 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

Intervention Type DRUG

HSK21542

Intravenous injection 3.375 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

Intervention Type DRUG

HSK21542

Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 2 min.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HSK21542 0.2 μg/kg HSK21542 0.5 μg/kg HSK21542 1 μg/kg HSK21542 1 μg/kg HSK21542 0.75 μg/kg HSK21542 1.5 μg/kg HSK21542 2.25 μg/kg HSK21542 3.375 μg/kg HSK21542 0.2 μg/kg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females aged 18-45 years old (inclusive) at screening;
2. Male volunteers no less than 50 kg, or female volunteers no less than 45 kg, with body mass index \[BMI\] in the range of 18.0-27.0 kg/m2 (inclusive) at screening;
3. Healthy volunteers, as assessed by the investigator based on past medical history, comprehensive physical examination, vital signs, and specified tests and examinations.
4. Fully understand the nature, purpose, and potential benefits, inconveniences and risks of the trial. Understand the study procedure and voluntarily provide written informed consent.
5. Able to communicate with the investigator and to follow all requirements of the study, and willing to be admitted into the phase I clinical facility.

Exclusion Criteria

1. Those who have suffered or are currently suffering from any clinical serious disease such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormality or any other disease or physiological condition that can interfere with the results;
2. Physical examination, vital sign monitoring, ECG examination, chest anteroposterior and lateral radiographs, laboratory examination (including blood routine, urine routine, blood biochemistry, coagulation function, thyroid function, blood pregnancy (only for female subjects) during screening period, and the researcher judged that the abnormality had clinical significance;
3. People with positive hepatitis B surface antigen, positive hepatitis C antibody, positive Treponema pallidum antibody, or positive AIDS virus antibody test;
4. Patients with QTcF\>450 ms in ECG examination during screening;
5. Allergic constitution: such as those who are allergic to two or more drugs and foods; Or those who are allergic to any ingredient in this product and auxiliary materials; (Auxiliary materials: glacial acetic acid, sodium acetate, water for injection)
6. Those who cannot tolerate venipuncture and/or have a history of blood and needle sickness;
7. Those who have drunk too much tea, grapefruit, coffee, caffeinated or grapefruit drinks for a long time (more than 8 cups a day, 1 cup=250mL);
8. Those who have a history of alcohol abuse within 3 months before screening, that is, those who drink more than 14 units of alcohol per week (1 unit=12 ounces or 360 mL of beer, 1.5 ounces or 45 mL of spirits with 40% alcohol content, 5 ounces or 150 mL of wine), or those who have positive alcohol breath test;
9. Volunteers with a positive urine nicotine test;
10. Volunteers with drug abuse or dependence, or with a positive urine drugs of abuse test;
11. Those who have used any prescription medicine, over-the-counter medicine, Chinese herbal medicine and health care products within 14 days
12. Blood donation or loss of blood \> 450 mL within the past 3 months;
13. Participation in any clinical trials within the past 3 months;
14. Volunteers who plan to become pregnant within the next 6 months;
15. Any other factors judged by the investigator to be unsuitable for participating in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes